首页> 外文期刊>Journal of oncology pharmacy practice: official publication of the International Society of Oncology Pharmacy Practitioners >Risk factors for cefepime nonsusceptible Gram-negative infections in allogeneic hematopoietic cell transplant recipients
【24h】

Risk factors for cefepime nonsusceptible Gram-negative infections in allogeneic hematopoietic cell transplant recipients

机译:一体化造血细胞移植受者的头孢术非脉冲革兰阴性感染的危险因素

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose Allogeneic hematopoietic cell transplant recipients undergo myelosuppressive chemotherapy to allow engraftment of stem cells and are at particularly high risk for bacterial infections and adverse outcomes. Patients undergoing hematopoietic cell transplant are at increased risk for healthcare-associated infections, including infections with multidrug-resistant pathogens. Cefepime is a commonly prescribed antibiotic for empiric therapy in hematopoietic cell transplant patients, but there is minimal data describing cefepime resistance rates, risk factors for resistance, and clinical outcomes associated with cefepime-resistant infections. Methods Adult (= 18 years old) allogeneic hematopoietic cell transplant recipients with a culture positive for a gram-negative rod between January 2010 and January 2016 were spilt into two groups: cefepime susceptible and cefepime nonsusceptible . The primary objective of this study was to identify risk factors for cefepime nonsusceptible through multivariable logistic regression. Results A total of 107 patients were included (27 cefepime nonsusceptible, 80 cefepime-susceptible), yielding a 25.2% nonsusceptibility rate. Multivariable analysis yielded age 60 years old, Klebsiella spp. infection, Acinetobacter spp. infection, healthcare exposures within 90 days, acute gastrointestinal graft-vs-host-disease, and chronic graft-vs-host-disease at multiple locations as significant risk factors for cefepime nonsusceptible. The receiver operating characteristic area under the curve of the model was 0.851. Thirty-day all-cause mortality (29.6% versus 16.3%, p = 0.13) and length of hospitalization (19 versus 12.5 days, p = 0.0650) were numerically higher in the cefepime nonsusceptible group. Conclusions Hematopoietic cell transplant patients with acute gastrointestinal graft versus host disease, extensive chronic graft-vs-host-disease, advanced age, previous healthcare exposures, or infections with Klebsiella and Acinetobacter are at increased risk for cefepime nonsusceptible. Patients infected with cefepime nonsusceptible pathogens may have higher rates of mortality and length of hospitalization.
机译:目的,同种异体造血细胞移植受体接受髓抑制化学疗法,以允许干细胞的植入,并特别高的细菌感染和不良结果的风险。接受造血细胞移植的患者正在增加医疗保健相关感染的风险增加,包括具有多药病原菌的感染。 Cefepime是造血细胞移植患者的经验疗法常见的抗生素,但是描述了最小的数据描述了头孢齿阻力率,抵抗危险因素,以及与头孢夫抗性感染相关的临床结果。方法成人(& = 18岁)同种异体造血细胞移植受者在2010年1月至2016年1月至1月至2016年1月之间呈培养阳性呈呈阳性呈阳性,分为两组:头孢卓易感和头脑无光血。本研究的主要目的是通过多变量逻辑回归识别头孢隙义Nonsconeptible的危险因素。结果共用了107名患者(27个活性无光精,80头脑敏感),产生25.2%的非排尿率。多变量分析产生时代& 60岁,Klebsiella SPP。感染,分枝杆菌SPP。感染,90天内的医疗曝光,急性胃肠植被 - 与宿主病,以及多个地点的慢性移植物 - 血液疾病,作为头孢术无创的重大风险因素。在模型曲线下的接收器操作特征区域为0.851。在头脑无创群体中,30天的全因死亡率(29.6%,P = 0.13)和住院时间(19.5天,P = 0.0650)在数值上更高。结论造血细胞移植患者急性胃肠移植患者与宿主病,广泛的慢性接枝 - 血液疾病,晚期,先前的医疗曝光,或患有Klebsiella和Acinetobacter的感染是在头孢卓的增加风险。感染头孢哌序无缝病原体的患者可能具有更高的死亡率和住院时间。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号